Spun out of work from Jan Kraus' lab at the University of Colorado in 2013, Orphan Technologies Ltd. has moved its first drug into the clinic. The Lexington, Mass.-based company is part of the Neopharm group, of Petach Tikva, Israel, a private company owned by a single family.
The global pharmaceutical market will surpass $1.5 trillion by 2023, according to a new report from Iqvia Institute for Human Data Science. That works out to a compounded annual growth rate of 3 percent to 6 percent over the next five years, which is, unfortunately, a slowdown from the 6.3 percent growth the industry has experienced over the past five years.
The global pharmaceutical market will surpass $1.5 trillion by 2023, according to a new report from Iqvia Institute for Human Data Science. That works out to a compounded annual growth rate of 3 percent to 6 percent over the next five years, which is, unfortunately, a slowdown from the 6.3 percent growth the industry has experienced over the past five years.
Bernard Gilly, co-founder and CEO of Gensight Biologics SA, was upbeat about the readout of Gensight's phase III Rescue study testing its gene therapy, GS-010, in patients with 11778-ND4 Leber hereditary optic neuropathy (LHON).
The global pharmaceutical market will surpass $1.5 trillion by 2023, according to a new report from Iqvia Institute for Human Data Science. That works out to a compounded annual growth rate of 3 percent to 6 percent over the next five years, which is, unfortunately, a slowdown from the 6.3 percent growth the industry has experienced over the past five years.
Following up on its 2017 $23.5 million series A financing, Lyndra Therapeutics Inc. secured $55 million in a series B round to support the development of its long-acting therapies. All of the previous investors resubscribed, while Hopu Investments, Gilead Sciences Inc., Invus, the Bill & Melinda Gates Foundation and Orient Life joined their ranks. (See BioWorld Today, April 14, 2017.)
Trevena Inc. had a painful end to 2018 with the FDA's Anesthetic and Analgesic Drug Products Advisory Committee voting 7-8 against recommending the proposed 0.1-mg and 0.35-mg doses of oliceridine, followed by a complete response letter (CRL) from the FDA the subsequent month.
